PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 15, 2026BMJ Open0 citationsOpen Access

KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic use (KIPRUN): protocol for a multicentre, randomised, superiority trial to compare the efficacy and safety of procalcitonin kinetics-guided and absolute procalcitonin value-guided antibiotic initiation in critically ill patients

View Full Paper
MPMárton PappCTC T TuranNKNikolett Kiss

Key Points

  • This trial aims to evaluate whether procalcitonin kinetics can more effectively guide antibiotic initiation compared to absolute procalcitonin values.
  • Multicentre, randomised controlled trial enrolling 250 critically ill adult patients in a 1:1 ratio.
  • Kinetics Group (KG) initiates antibiotics if procalcitonin levels increase by over 100%; Absolute Group (AG) initiates based on a single procalcitonin measurement above 0.5 ng/mL.
  • Primary outcome is the rate of unnecessary antibiotic therapy assessed by an independent review team after 72 hours.
  • The main outcome will determine the rate of unnecessary antibiotic therapy based on consensus among healthcare professionals after 72 hours.

Abstract

Introduction Appropriate antibiotic (AB) therapy remains a challenge in intensive care units (ICUs). Guidelines recommend against using procalcitonin (PCT) to guide the initiation of AB therapy, although with low certainty and a very low level of evidence. Recent studies suggest that changes in PCT levels may be more accurate than a single measurement; however, this has never been tested in a randomised trial. Methods and analysis In this multicentre, randomised controlled trial (RCT), we aim to compare the efficacy and safety of two different PCT protocols for initiating AB therapy. Hemodynamically stable, critically ill adult patients with suspected new-onset infection at admission or during ICU stay will be randomised in a 1:1 ratio. In the treatment arm (Kinetics Group, KG), initiation of AB treatment is strongly recommended if PCT ≥0.5 ng/mL and increases by more than 100% compared with the previous day. In the control arm (Absolute Group, AG), the initiation of AB treatment is strongly recommended if PCT ≥0.5 ng/mL. The primary outcome will be the rate of unnecessary AB therapy: 72 hours after recruitment, an independent intensivist, microbiologist and infectologist will determine whether the therapy was necessary, using all relevant clinical, microbiological and radiographic results. If no consensus is reached, a decision will be made by secret vote. We plan to enrol 250 participants in the study, with 80% statistical power and a 5% alpha level. Ethics and dissemination Ethics approval was obtained from the National Centre for Public Health and Pharmacy (BM/20019/2025). We plan to present our results at relevant national and international conferences and meetings and to submit them for publication in a peer-reviewed journal. Moreover, we plan to disseminate the results to important stakeholders in the Hungarian healthcare system. Trial registration number This is the first version of the trial protocol, prepared in accordance with the SPIRIT 2025 guideline (version 1.0, dated 30 September 2025). The trial has been registered on ClinicalTrials.gov ( NCT07211620 ).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Papp et al. (2026) studied this question.

synapsesocial.com/papers/6a06b940e7dec685947abde7https://doi.org/10.1136/bmjopen-2025-115344
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improve Management of Acute Heart Failure with ProcAlCiTonin in EUrope: Results of the Randomized Clinical Trial IMPACT EU Biomarkers in Cardiology (BIC) 182019 · 29 citations
  2. 2Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: The PEACH mixed methods study2025
  3. 3Procalcitonin Algorithms for Antibiotic Therapy Decisions2011 · 388 citations
  4. 4Implementation of procalcitonin-guided antibiotic stopping advice in sepsis: A mixed-methods process evaluation in a clinical trial context2026
  5. 5Procalcitonin kinetics in Gram-negative bloodstream infections and its value for infection management2026